Xynomic Pharmaceuticals
China - ShanghaiPharmaceutical
Focus: Xynomic Pharmaceuticals is a small-molecule oncology and neurology-focused company headquartered in Shanghai developing multiple cancer immunotherapy and targeted agents. The company operates with minimal public visibility and an early-stage pipeline concentrated in hematologic and solid malignancies.
Profile data last refreshed 11h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Xynomic Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Xynomic Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Xynomic Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Abexinostat
Diffuse Large B-cell LymphomaAbexinostat
Stage III Cutaneous MelanomaClinical Trials (1)
Help build intelligence for Xynomic Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.